Not to self diagnose but something is wrong
Quand on pense qu’il ni a plus rien… y’a encore un peu de vie!
Follow her on Instagram: Tardibabe / Chloé Savard
https://instagram.com/tardibabe?igshid=YmMyMTA2M2Y=
Stop the ban on blood donation of gay men
Researchers at University of California San Diego School of Medicine have discovered one way in which SARS-CoV-2, the coronavirus that causes COVID-19, hijacks human cell machinery to blunt the immune response, allowing it to establish infection, replicate and cause disease.
In short, the virus’ genome gets tagged with a special marker by a human enzyme that tells the immune system to stand down, while at the same time ramping up production of the surface proteins that SARS-CoV-2 uses as a “doorknob” to enter cells.
The study, published April 22, 2021 in Cell Reports, helps lay the groundwork for new anti-viral immunotherapies — treatments that work by boosting a patient’s immune system, rather than directly killing the virus.
“It’s very smart of this virus to use host machinery to simultaneously go into stealth mode and get inside more cells,” said Tariq Rana, PhD, professor and chief of the Division of Genetics in the Department of Pediatrics at UC San Diego School of Medicine and Moores Cancer Center. “The more we know about how the virus establishes itself in the body, the better equipped we are to disrupt it.”
In human cells, genes (DNA) are transcribed into RNA, which is then translated into proteins, the molecules that make up the majority of cells. But it’s not always so straightforward. Cells can chemically modify RNA to influence protein production. One of these modifications is the addition of methyl groups to adenosine, one of the building blocks that make up RNA. Known as N6-methyladenosine (m6A), this modification is common in humans and other organisms, including viruses.
In contrast to humans, the entire genomes of some viruses, including SARS-CoV-2, are made up of RNA instead of DNA. And rather than carry around the machinery to translate that into proteins, the coronavirus gets human cells to do the work.
Rana and his team previously discovered that m6A plays an important role in HIV and Zika virus infections. In their latest study, the researchers discovered that the human enzyme METTL3 adds methyl groups to introduce m6A in SARS-CoV-2’s RNA. That modification prevents the virus’ RNA from triggering inflammatory molecules known as cytokines. To the team’s surprise, METTL3’s activity also led to increased expression of pro-viral genes — those that encode proteins needed for SARS-CoV-2 replication and survival, such as ACE2, the cell surface receptor that the virus uses to enter human cells.
“It remains to be seen why our cells help the virus out like this,” Rana said.
biologists will be like this is a very simplified diagram of a mammalian cell
chemists will be like this is a molecule
Neil Druckmann - HBO's The Last of Us Podcast: Episode 5
Stop the ban on blood donation of gay men
fruitie punches
leaving a three hour lab be like:
what time is it? why is it dark outside? where did the sun go?
I'm starving.
I'm never doing that again (literally has the same lab scheduled the following week).
The bacteria wars are coming. Researchers at Tel Aviv University have pitted “good” bacteria against “bad” bacteria and the good guys, it appears, are winning.
If the system can be scaled, this new approach could potentially replace antibiotics, which are increasingly struggling against antibiotic-resistant “superbugs.” For the TAU study, the researchers used a toxin injection system known as a “Type 6 Secretion System.” It’s usually deployed by pathogenic (“bad”) bacteria. They introduced the system into a “friendly” bacterium, Vibrio natriegens, which is not harmful to humans. The researchers described their technology as similar to a microscopic poison arrow shot from a good bacterium to eliminate a bad bacterium under specific conditions. “The system that we built allows us to engineer ‘good’ bacteria that can recognize pathogenic bacteria, attack them with toxins, and neutralize them,” explains Dr. Dor Salomon, who co-led the study. “We know how to change and control every component in the system and create a bacterium that neutralizes different strains of bacteria. This is proof of feasibility, showing that we have the knowledge and ability to create bacteria that take advantage of this killing system and may serve as antibiotic treatments. ”The current bacteria prototype is best suited for bugs that occur naturally in saltwater. This is a growing concern, as fish and seafood constitute a major food source in many regions of the world. “Their productivity is severely impaired as a result of bacteria-borne diseases,” Solomon notes, “and since we want to avoid pouring antibiotics into aquaculture farms, a biological solution such as the one we have developed is an effective alternative.” The system will eventually be adapted to treat pathogenic bacteria in humans, farm animals and plants. Tel Aviv University has filed a patent application through Ramot, the university’s technology-transfer company. In addition to Solomon, Dr. Biswanath Jana and Kinga Kappel of the department of clinical microbiology and immunology at TAU’s Sackler Faculty of Medicine participated in the research. The results were published this month in the scientific journal EMBO Reports.